Select Page

The Global Ophthalmic Devices Market, a part of the HEALTHCARE industry, grew at a compound annual growth rate (CAGR) of around 6% during the historic period. The HEALTHCARE industry showed a steady growth. The growth is mainly due to a growing aging population, a rise in number of eye diseases and technological advancements in ophthalmology devices.

In the forecast period, the global ophthalmic devices market size is expected to be over $36 billion by 2021, growing at a CAGR of nearly 4%. This is expected due to the use of robotic systems in the field of ophthalmology is increasing. Conventional ophthalmic surgeries are generally performed with a high magnification with a three-dimensional view through a surgical microscope and precise manipulations are made using delicate handheld instruments to minimize collateral damages. Furthermore, rising population, increase in dispensable income, and increasing per capita incomes are expected to drive the global ophthalmic devices market in the future.

Find TBRC’s report on the ophthalmic devices market:

Venture capital firms are investing in major ophthalmology device manufacturing companies to take advantage of the growth in the market and the potential of new technologies within it. Venture capital firms such as Versant, SV Life Sciences, InterWest Partners, Domain Associates, Polaris, and others are investing in major competitors in the market such as Alcon, Abbott Medical Optics, and Bausch & Lomb.

Major companies in the ophthalmic devices market, offering new technology include Essilor International, Alcon and Johnson & Johnson.

Download a sample report:

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293


Follow us on LinkedIn: